Curetis AG Strengthens Commercial Team and Expands Distribution Network
News Mar 11, 2013
Curetis AG has announced the appointment of Helmut Hilbert as Head of Business Development and the expansion of its distribution network into Belgium and Luxembourg by closing a distribution agreement with ELITech BNL (former Lucron Bioproducts), an ELITech Group company.
In order to strengthen its global commercial operations, Curetis has hired Dr. Helmut Hilbert, formerly Associate Director Corporate Business Development at Qiagen, as Head of Business Development.
Helmut Hilbert has more than ten years of business and corporate development experience and built a strong track record in licensing, mergers and acquisitions, technology transfer and innovation management.
At Qiagen, he was responsible for scouting novel technologies as well as evaluating potential acquisition targets and investment opportunities, including contract negotiation, due diligences and post-merger integration.
Moreover, Curetis has selected ELITech BNL as its Belgian and Luxembourgian distribution partner. ELITech BNL (former Lucron Bioproducts) has a long-standing track record as a distributor of quality diagnostic products and research supplies in the Benelux.
Among others, the company supported the market entry of Cepheid into these countries.
Acquired by the global in vitro diagnostics distributor ELITech Group in 2010, ELITech BNL is part of an extensive commercial network covering France, Italy, the UK and the rest of the world.
“Having built a successful business for Cepheid and the GeneXpert system in the Benelux, we are excited about the opportunity presented by the Curetis Unyvero Solution,” said Frank Loots, General Manager of ELITech BNL.
Loots continued, “We are planning a commercial roll-out and market introduction phase here in Belgium and in Luxembourg to begin with leading clinicians and institutions in our territories.”
“With the appointment of Helmut Hilbert as Head of Business Development and the distribution agreement with ELITech, we continue our accelerated commercial development progress,” said Oliver Schacht, CEO of Curetis.
Schacht continued, “The growing awareness for the Unyvero™ System allows us to attract experienced employees and renowned corporate partners and to expand our operations. We are in the process of growing our business in the Middle East with additional placements in Dubai, Saudi Arabia and Qatar over the next couple of months. In addition, our customer order book continues to expand significantly - we currently have a waiting list of more than fifty top-tier institutions worldwide.”
Should Historic Doping Issues Strip All Athletes of World Records?News
A proposal had been put forward by the European Athletics Council to disregard all world records set before 2005 due to issues with doping. However, a recent publication suggests these plans should be abolished.READ MORE
Infrared Spectroscopy Test Can Diagnose Two Cancer TypesNews
Researchers used mid-infrared spectroscopy to analyze blood serum derived from experimental mice and differentiate mice with non-Hodgkin’s lymphoma and subcutaneous melanoma from healthy mice and also between these two tumorous conditions.READ MORE
IDEX Health & Science Announces Acquisition of New Microfluidics CompanyNews
IDEX Health & Science, LLC announced the acquisition of thinXXS Microtechnology that will accelerate growth of its microfluidics consumables business.READ MORE